Brokers Offer Predictions for Galecto FY2029 Earnings

Galecto, Inc. (NASDAQ:GLTO) – Analysts at Leerink Partnrs issued their FY2029 earnings estimates for shares of Galecto in a research report issued to clients and investors on Wednesday, February 5th. Leerink Partnrs analyst T. Smith anticipates that the company will earn ($4.14) per share for the year. The consensus estimate for Galecto’s current full-year earnings is ($15.59) per share.

Separately, Oppenheimer raised their price target on shares of Galecto from $9.00 to $10.00 and gave the stock an “outperform” rating in a report on Thursday, October 17th.

Galecto Stock Performance

NASDAQ GLTO opened at $4.98 on Friday. The stock’s 50 day simple moving average is $5.20 and its 200-day simple moving average is $8.48. Galecto has a 1-year low of $4.40 and a 1-year high of $23.50.

About Galecto

Galecto, Inc, a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB2064, a selective oral small molecule inhibitor of LOXL2 that is in Phase 2a clinical trial for the treatment of fibrotic diseases, including cancer and myelofibrosis; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis.